Anocca Raises SEK 440 Million to Advance TCR-T Cell Therapy Development

Anocca secures major financing for T-cell immunotherapy

Anocca AB, a clinical-stage biopharmaceutical company based in Sweden, has successfully raised approximately SEK 440 million (USD 46 million) in a new financing round. This funding will accelerate the development of VIDAR-1, Anocca’s gene-edited TCR-T cell therapy targeting mutant KRAS in pancreatic cancer, and support its preclinical programs.

The round was led by Mellby Gård with participation from AMF, Ramsbury, existing shareholders, and new investors — strengthening Anocca’s position as a leading clinical-stage biotech in Sweden.

Phase I trial recruitment underway

Anocca has now opened recruitment for the Phase I clinical trial of VIDAR-1, which will take place at university hospitals in Sweden, Denmark, Germany, and the Netherlands. This milestone marks a significant step toward bringing TCR-T cell therapies to patients with solid tumours.

CEO Reagan Jarvis thanked investors for their continued support and highlighted the company’s progress in advancing its first TCR-T therapy to clinical stages. Mellby Gård Chairman Johan Andersson emphasized Anocca’s transition into a clinical-stage biotech company as a key achievement.

Expert advisors guide the financing

• Financial advisor: SEB Corporate Finance

• Legal advisors: Mannheimer Swartling and HWF Advokater

These partnerships ensure that Anocca’s funding and regulatory processes are aligned with best practices in the Swedish biopharmaceutical industry.

About Anocca AB

Founded in Södertälje, Sweden, Anocca AB is a fully integrated biopharmaceutical company developing T-cell receptor-engineered T cell (TCR-T) therapies for solid tumours and other diseases. With proprietary technologies, in-house manufacturing, and a team of over 130 professionals from 40+ countries, Anocca is at the forefront of innovative immunotherapy research in Sweden.